RESEARCH SUPPORT, NON-U.S. GOV'T
LH-RH nasal spray treatment for cryptorchidism. A double-blind, placebo-controlled study.
A double-blind, placebo-controlled study of the efficacy of LH-RH nasal spray in treatment of cryptorchidism involving 252 prepuberal boys with 301 undescended testes, showed a success rate of 9% (14 testes) for LH-RH and 8% (10 testes) for placebo. Including a subsequent open study and a second course of LH-RH as required, the rate for LH-RH rose to 18% (48 testes). The follow-up period saw late descent in another 5% (14 testes), in a few cases coinciding with the onset of puberty. Retrospective evaluation revealed a previous scrotal position of the testes for 43% of the boys with success of treatment and even for 17% of the boys with failure of treatment. In many of these cases surgery revealed an anatomical anomaly that might have caused testicular ascent. Hormonal evaluation revealed no abnormalities in cryptorchid boys compared with control subjects, nor was there a divergence in values before and after treatment. The lower the pretreatment testicular position, the better the rate of success.
Full text links
Trending Papers
Management of Hyponatremia in Heart Failure: Practical Considerations.Journal of Personalized Medicine 2023 January 11
Systemic complications of rheumatoid arthritis: Focus on pathogenesis and treatment.Frontiers in Immunology 2022
Management of heart failure in patients with kidney disease - updates from the 2021 ESC guidelines.Nephrology, Dialysis, Transplantation 2023 January 24
2023 American Society of Anesthesiologists Practice Guidelines for Preoperative Fasting: Carbohydrate-containing Clear Liquids with or without Protein, Chewing Gum, and Pediatric Fasting Duration-A Modular Update of the 2017 American Society of Anesthesiologists Practice Guidelines for Preoperative Fasting.Anesthesiology 2023 Februrary 2
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app